DNA Replication Licensing Factors: Novel Targets for Cancer Therapy via Inhibiting the Stemness of Cancer Cells

Int J Biol Sci. 2022 Jan 1;18(3):1211-1219. doi: 10.7150/ijbs.67529. eCollection 2022.

Abstract

The replication licensing factors strictly regulate the DNA replication origin licensing process to guarantee the stability of the genome. Numerous experimental studies have recently demonstrated that the replication licensing factors as oncogenes are essential for the occurrence and development of cancers. Drug resistance, being one of the main characteristics of cancer stem cells, can cause a high recurrence rate and a low survival rate in patients with different cancers. However, the function of the replication licensing factors in cancer stemness remains unclear. The following article highlights the most recent research on DNA replication origin licensing factors in cancer and their function in anti-cancer drug resistance. Moreover, this article proposes a new perspective that replication licensing factors as chemotherapy shield affect anti-cancer drug resistance by promoting the stemness of cancer cells.

Keywords: cancer stem cell; drug resistance; replication initiation factors; stemness.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antineoplastic Agents* / pharmacology
  • Antineoplastic Agents* / therapeutic use
  • Cell Cycle Proteins / metabolism
  • DNA / genetics
  • DNA Replication / genetics
  • Humans
  • Neoplasms* / drug therapy
  • Neoplasms* / genetics
  • Oncogenes
  • Replication Origin

Substances

  • Antineoplastic Agents
  • Cell Cycle Proteins
  • DNA